Seattle Genetics, Inc. (SGEN)
Stock Price Chart
Key Info
| Market Cap | 27.92B |
| Revenue (ttm) | 1.02B |
| Net Income (ttm) | -255.68M |
| Shares Out | 174.00M |
| EPS (ttm) | -1.49 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Aug 7, 2020 |
| Last Price | $160.45 |
| Previous Close | $161.80 |
| Change ($) | -1.35 |
| Change (%) | -0.83% |
| Day's Open | 161.52 |
| Day's Range | 158.74 - 162.75 |
| Day's Volume | 727,652 |
| 52-Week Range | 65.44 - 187.99 |
More Stats
| Market Cap | 27.92B |
| Enterprise Value | 27.09B |
| Earnings Date (est) | Oct 22, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 174.00M |
| Float | 125.19M |
| EPS (basic) | -1.48 |
| EPS (diluted) | -1.49 |
| FCF / Share | -1.80 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 4.21M |
| Short Ratio | 3.68 |
| Short % of Float | 7.32% |
| Beta | 1.41 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 27.49 |
| PB Ratio | 15.59 |
| Revenue | 1.02B |
| Operating Income | -334.52M |
| Net Income | -255.68M |
| Free Cash Flow | -312.41M |
| Net Cash | 832.01M |
| Net Cash / Share | 4.78 |
| Gross Margin | 15.10% |
| Operating Margin | -32.94% |
| Profit Margin | -25.20% |
| FCF Margin | -30.76% |
| ROA | -11.20% |
| ROE | -16.57% |
| ROIC | -18.40% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 917 | 655 | 482 | 418 | 337 | 287 | 269 | 211 | 94.78 | 107 |
| Revenue Growth | 40.02% | 35.76% | 15.33% | 24.15% | 17.45% | 6.5% | 27.73% | 122.43% | -11.81% | - |
| Gross Profit | 873 | 566 | 428 | 376 | 299 | 258 | 248 | 197 | 91.66 | 107 |
| Operating Income | -221 | -260 | -196 | -143 | -121 | -77.36 | -62.86 | -57.25 | -144 | -68.20 |
| Net Income | -159 | -223 | -126 | -140 | -120 | -76.14 | -62.52 | -53.78 | -152 | -66.27 |
| Shares Outstanding | 165 | 158 | 143 | 141 | 129 | 123 | 122 | 118 | 113 | 101 |
| Earnings Per Share | -0.96 | -1.41 | -0.88 | -1.00 | -0.93 | -0.62 | -0.51 | -0.46 | -1.34 | -0.66 |
| Operating Cash Flow | -164 | -204 | -119 | -96.97 | -133 | -60.00 | -1.11 | 10.88 | -124 | 6.81 |
| Capital Expenditures | -70.75 | -21.22 | -70.38 | -27.84 | -13.39 | -17.18 | -22.15 | -10.49 | -11.25 | -3.55 |
| Free Cash Flow | -234 | -225 | -189 | -125 | -147 | -77.18 | -23.26 | 0.40 | -135 | 3.26 |
| Cash & Equivalents | 811 | 411 | 413 | 589 | 650 | 313 | 374 | 364 | 331 | 282 |
| Total Debt | 67.61 | - | - | - | - | - | - | - | - | - |
| Net Cash / Debt | 743 | 411 | 413 | 589 | 650 | 313 | 374 | 364 | 331 | 282 |
| Assets | 2,206 | 1,503 | 878 | 838 | 895 | 459 | 484 | 471 | 425 | 330 |
| Liabilities | 330 | 229 | 200 | 204 | 209 | 248 | 254 | 245 | 206 | 168 |
| Book Value | 1,876 | 1,274 | 678 | 634 | 686 | 211 | 230 | 226 | 219 | 162 |
Company Profile
Company Details
| Full Name | Seattle Genetics, Inc. |
| Country | United States |
| Employees | 1,605 |
| CEO | Clay B. Siegall |
Stock Information
| Ticker Symbol | SGEN |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Unique Identifier | NASDAQ: SGEN |
Description
Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; and PADCEV, an ADC composed of an anti-Nectin-4 monoclonal antibody for the treatment of metastatic urothelial cancers. It also develops Tucatinib, an investigational oral, small molecule TKI for HER2, a growth factor receptor; and Tisotumab Vedotin, an ADC composed of a human antibody that binds to tissue factor to treat various solid tumors, including cervical, ovarian, prostate, and bladder. In addition, the company develops ladiratuzumab vedotin, an ADC targeting LIV-1 and metastatic triple-negative breast cancer; SEA-BCMA, a clinical-stage non-fucosylated BCMA-directed antibody for patients with relapsed or refractory multiple myeloma. Seattle Genetics, Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; and biotechnology and pharmaceutical companies. Seattle Genetics, Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.